

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
DAVCO-42403SERIAL NO.
08/815,933

INFORMATION DISCLOSURE CITATION

(Use Several Sheets if Necessary)

APPLICANT

Christopher R. Parish

FILING DATE

March 13, 1997

GROUP

1806

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPLICABLE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO
NAS	WO 90/12585	11/1/90	PCT	—	—		
NAS	EP 457532	11/21/91	EPO	—	—		
NAS	EP 407122	1/9/91	EPO	—	—		
NAS	WO 87/01372	3/12/87	PCT	—	—		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

NAS	Hagemeier, Int. J. Cancer Res. 38: 481-488, 1986 —
NAS	Vitetta, Science 238: 1098-1104, 1987
NAS	Goldenberg et al. Ch. 13, in Immunoconjugate 1987 pp. 259-280 Oxford Univ. Press, NY
NAS	Wang, Angiogenesis EXS 61: 266-271, April 22, 1992 —
NAS	Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature; Vol. 90, pp. 8996-9000, October 1993, Medical Sciences —
NAS	Biochemical & Biophysical Research Communications, Vol. 194, No. 3, issued 16 August, 1993, Kondo S et al; "Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth and its inhibition by the antibody" pages 1234-1240 ✓
NAS	Tissue & Cell, Vol. 19, No. 4, 1987, M.E. Schelling et al; "Immunochemical comparison of peptide angiogenic factors" pages 463-467
NAS	Harris, TIBTECH 11: 42-44, 1993

EXAMINER

N. Johnson

DATE CONSIDERED

1/15/98

EXAMINER

Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.